Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Pharmanutra S.p.A., a leading name in the pharmaceutical preparation manufacturing industry, is headquartered in Italy and operates extensively across Europe and beyond. Founded in 2003, the company has established itself as a pioneer in the development of innovative nutritional supplements and medical devices, particularly those based on iron and mineral formulations.
Pharmanutra's core products, including the renowned SiderAL® line, are distinguished by their unique formulations that enhance bioavailability and absorption, setting them apart in a competitive market. With a commitment to research and development, the company has achieved significant milestones, including numerous patents and collaborations with healthcare professionals.
Recognised for its quality and efficacy, Pharmanutra continues to strengthen its market position, contributing to advancements in health and wellness through scientifically-backed solutions.
-6 vs industry average
Pharmanutra’s score of 34 is lower than 48% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Pharmanutra, an Italian pharmaceutical preparation manufacturer, has reported its carbon emissions for the period 2020-2024.
For 2024, Pharmanutra's total Scope 1 and Scope 2 emissions were approximately 1,696,000 kg CO2e. This comprised approximately 220,000 kg CO2e from Scope 1 emissions and about 1,476,000 kg CO2e from Scope 2 emissions (market-based).
In 2023, the company reported approximately 229,000 kg CO2e for Scope 1 emissions and about 457,000 kg CO2e for Scope 2 emissions (market-based).
For 2022, Pharmanutra's Scope 1 emissions were approximately 199,000 kg CO2e, and its Scope 2 emissions (market-based) were about 58,000 kg CO2e.
The company's Scope 1 emissions in 2021 amounted to approximately 137,965 kg CO2e, with Scope 2 emissions (market-based) of about 42,922 kg CO2e.
In 2020, Pharmanutra's Scope 1 emissions were approximately 92,590 kg CO2e, and its Scope 2 emissions (market-based) were about 39,720 kg CO2e.
Pharmanutra's reporting for all these years indicates that Scope 3 emissions data, specifically for purchased goods and services, is currently missing. The company has not disclosed specific reduction targets or commitments to SBTi or the Climate Pledge.
Access structured emission data, company specific factors and auditable source documents
No climate goals have been disclosed for Pharmanutra yet.
No scope 3 category breakdown has been disclosed yet.


You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more